List view / Grid view
23 December 2013 | By Lundbeck
New research reveals that genetic variations that increase the risk of developing schizophrenia have a direct and harmful effect on the brain, impairing the intellectual and cognitive function of people with these variations...
23 December 2013 | By Daiichi Sankyo Company
Daiichi Sankyo Company has received supplemental new drug application (sNDA) approval for Topotecin® injection 40 mg and 100 mg (irinotecan hydrochloride hydrate) for unresectable pancreatic cancer.
23 December 2013 | By Daiichi Sankyo Company
Daiichi Sankyo has received approval in Japan to market Inavir® Dry Powder Inhaler 20mg (generic name: Laninamivir Octanoate Hydrate)...
20 December 2013 | By Roche
“This positive opinion from the CHMP is a step toward providing physicians and patients the flexibility to choose whether intravenous or subcutaneous RoActemra treatment..."
20 December 2013 | By Merck
This business is based on providing weight management interventions that combine a structured diet, behavior coaching...
20 December 2013 | By Daiichi Sankyo
Inavir® is a long-acting neuraminidase inhibitor developed by Daiichi Sankyo which is manufactured in Japan...
19 December 2013 | By Sanofi
Collaboration represents the first time the ACC’s PINNACLE Registry Research Alliance will be used for clinical trial recruitment...
19 December 2013 | By Sandoz
Sandoz advances leading biosimilars pipeline by strengthening Immunology portfolio...
19 December 2013 | By AstraZeneca
Global agreement strengthens AstraZeneca’s commitment to diabetes, a key growth platform in a core strategic area for the company...
19 December 2013 | By Daiichi Sankyo Company
Daiichi Sankyo is seeking approval in Japan for edoxaban in new indications for non-valvular atrial fibrillation (AF) and symptomatic venous thromboembolism...
18 December 2013 | By Merck
“Collaborations like this are central to Merck’s strategy to evaluate the potential of MK-3475 for the treatment of cancer..."
17 December 2013 | By Amgen
Study meets co-primary endpoints of LDL cholesterol reduction...
17 December 2013 | By Abbott
This highly advanced diagnostic tool measures the internal optics and surface of the eye more precisely than conventional methods...
17 December 2013 | By
AstraZeneca is aware of reports that an 505(b)(2) NDA esomeprazole strontium product has been launched in the US by Hanmi Pharmaceutical and affiliates...
17 December 2013 | By GlaxoSmithKline
GSK sets out plans to evolve the way it sells and markets its products to healthcare professionals...
